Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Seer, Inc.NASDAQ: SEER

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$15.3M, compared with -$18.25M a year earlier. Trailing-twelve-month EBITDA was -$64.35M.

Context

  • EBITDA amounted to 417.5% of revenue in FY2025, down 158.4 pp from a year earlier.
  • EBITDA grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of -$52.97M (+21.3%) for the fiscal year ending Dec 2026, a step up from the +16.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$15.3M-5.8% QoQ
Last fiscal yearDec 2025
-$67.3M+16.2% YoY
LTMMar 2026
-$64.35M+18.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.2%+24.2%+8.1 pp
1 year+16.2%+21.3%+5.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(67.3M) USD
Year-over-year change
+16.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +18.9% is the 4th highest of 19, against a peer median of -4.5%.
  • EBITDA amounts to 427.9% of revenue for SEER, versus a peer median of 287.9%.
SEER Competitors
EBITDA for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$322.61M USD+243.1%—46.0%
MNOVMediciNova, Inc.LTM Mar 2026-$11.72M USD-5.2%—1963.7%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026-$35.85M USD-213.1%——
STTKShattuck Labs, Inc.LTM Mar 2026-$46.23M USD+30.8%—4623.1%
MOLNMolecular Partners AGLTM Mar 2026-CHF 63.08M CHF-8.3%——
SEERSeer, Inc.LTM Mar 2026-$64.35M USD+18.9%—427.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-$72.53M USD+7.7%—257.0%
PEPGPepGen Inc.LTM Mar 2026-$75.99M USD+22.0%——
NKTXNkarta, Inc.LTM Mar 2026-$90.7M USD+10.7%——
QSIQuantum-Si incorporatedLTM Mar 2026-$99.13M USD-3.1%—5352.8%
CCCCC4 Therapeutics, Inc.LTM Mar 2026-$100.38M USD-3.7%—287.9%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026-$123.54M USD-796.7%—287.6%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$134.03M USD-1.8%——
PHVSPharvaris N.V.LTM Sep 2026-€184.94M EUR-15.5%——
SANASana Biotechnology, Inc.LTM Mar 2026-$187.06M USD+2.3%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$220.73M USD-23.8%——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$238.99M USD-27.7%—770932.3%
KYMRKymera Therapeutics, Inc.LTM Jun 2026-$291.43M USD-9.1%—277.6%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026-$349.54M USD-83.3%——
Peer median (excluding SEER) —-4.5%—287.9%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.